January 08, 2025--(BUSINESS WIRE)--MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced the in ...
This year will also doubtlessly bring deals involving artificial intelligence and related technologies. Experts predict that 2025 will be the year AI becomes ubiquitous in chemistry. It’s already ...
--(BUSINESS WIRE)--MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced the in-licensing of a ...
NEW YORK – MOMA Therapeutics on Wednesday said it added the next-generation PARP1 inhibitor MOMA-989 to its pipeline of drug candidates and anticipates filing an investigational new drug application ...
MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced the in-licensing of a next-generation selective ...
Moma Therapeutics Inc. has in-licensed a next-generation selective poly(ADP-ribose) polymerase 1 (PARP-1) inhibitor, now known as MOMA-989.
The Google cofounder has donated more than $1.5 billion to Parkinson’s research. Now, as he takes on autism, he’s also ...
Patient advocate Austin Leclaire, who died Feb. 1, played a pivotal role in spurring the development of the first medicines ...
MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced the in-licensing of a next-generation selective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback